3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Lymphoid
5
Myeloid
4
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
79
Carboplatin
66
pembrolizumab
61
Bevacizumab
56
Cisplatin
48
Specimen Handling
29
Drug Therapy
26
Blood Specimen Collection
24
Cyclophosphamide
20
olaparib
19
Taxes
17
Magnetic Resonance Spectroscopy
16
Letrozole
16
Gemcitabine
16
Biopsy
16
liposomal doxorubicin
15
niraparib
14
fludarabine
14
Brachytherapy
14
Radiotherapy
13
abemaciclib
12
Topotecan
11
Nivolumab
11
Injections
11
Doxorubicin
11
lenvatinib
10
Fluorouracil
10
Surveys and Questionnaires
9
Standard of Care
9
Oxaliplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Blood Component Removal
×
Gynecologic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled